HuCD34-NCG Mouse

NCG mice are humanized by adoptive transfer of human umbilical cord blood-derived CD34+ stem cells from a qualified source, following myeloablation treatment. Animals are subsequently housed for 12-15 weeks according to Charles River immunodeficient animal housing protocols while the human CD34+ stem cells stably engraft within the immunodeficient NCG mice.Human immune cells can be detected in the peripheral blood as early as 12 – 15 weeks post-engraftment. These immune cells can also be detected in mouse tissues, including bone marrow, spleen, liver, and lung at later time points.The HuCD34-NCG are an ideal in vivo platform to evaluate the effectiveness of compounds that function by modulating the human immune system. The lack of, or late onset of, graft-versus-host disease (GvHD) in these engrafted animals makes them ideal for longer term studies.NCG Mouse OriginThe NCG mouse was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014, and transferred to Charles River in 2016. This model was created by sequential CRISPR/Cas9 editing of the Prkdc and Il2rg loci in the NOD/Nju mouse, generating a mouse coisogenic to the NOD/Nju.The NOD/Nju carries a mutation in the Sirpa (SIRP α) gene that allows for engrafting of foreign hematopoietic stem cells. The Prkdc knockout generates a SCID-like phenotype lacking proper T cell and B cell formation. The knockout of the Il2rg gene further exacerbates the SCID-like phenotype while additionally resulting in a decrease of NK cell production.